New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - fusidic acid 20.35 mg/g (as the 0.5 hydrate) - topical cream - 20 mg/g - active: fusidic acid 20.35 mg/g (as the 0.5 hydrate) excipient: butylated hydroxyanisole cetyl alcohol glycerol hydrochloric acid liquid paraffin polysorbate 60 potassium sorbate purified water white soft paraffin - indicated either alone or in combination with systemic therapy, in the treatment of primary and secondary skin infections caused by sensitive strains of staphylococcus aureus, streptococcus spp and corynebacterium minutissimum. primary skin infections that may be expected to respond to treatment with fusidic acid applied topically include: impetigo contagiosa, superficial folliculitis, sycosis barbae, paronychia and erythrasma; also such secondary skin infections as infected eczematoid dermatitis, infected contact dermatitis and infected cuts/abrasions.

New Zealand - English - Medsafe (Medicines Safety Authority)

medsurge pharma limited - tranexamic acid 100 mg/ml;   - solution for injection - 500 mg/5ml - active: tranexamic acid 100 mg/ml   excipient: hydrochloric acid sodium hydroxide water for injection - haemorrhage or risk of haemorrhage in increased fibrinolysis or fibrinogenolysis. local fibrinolysis may occur in the following conditions: - prostatectomy and bladder surgery - menorrhagia - epistaxis - conisation of the cervix - management of dental extraction in patients with coagulopathies - ulcerative colitis - haematuria (tranexamic acid therapy is not indicated in haematuria caused by diseases of the renal parenchyma (also see precautions). - gastrointestinal haemorrhage.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ursodeoxycholic acid, quantity: 250 mg - capsule - excipient ingredients: titanium dioxide; maize starch; silicon dioxide; gelatin; magnesium stearate - ursodeoxycholic acid is indicated in the treatment of chronic cholestatic liver diseases.

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - tranexamic acid, quantity: 100 mg/ml - injection - excipient ingredients: water for injections; hydrochloric acid; sodium hydroxide - adults for the reduction of peri? and post-operative blood loss and the need for blood transfusion in patients undergoing cardiac surgery or total knee arthroplasty or total hip arthroplasty. paediatrics for the reduction of peri? and post-operative blood loss and the need for blood transfusion in patients undergoing cardiac surgery.

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - tranexamic acid, quantity: 100 mg/ml - injection - excipient ingredients: water for injections; hydrochloric acid; sodium hydroxide - adults for the reduction of peri? and post-operative blood loss and the need for blood transfusion in patients undergoing cardiac surgery or total knee arthroplasty or total hip arthroplasty. paediatrics for the reduction of peri? and post-operative blood loss and the need for blood transfusion in patients undergoing cardiac surgery.

Australia - English - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - aminolevulinic acid hydrochloride, quantity: 10.2 mg (equivalent: aminolevulinic acid, qty 8 mg) - patch, dermal - excipient ingredients: polyethylene terephthalate; polyethylene; aluminium; ethyl acetate; acrylic acid; 2-ethylhexyl acrylate; methyl acrylate; glycidyl methacrylate; 2,2'-azobisisobutyronitrile; hexane - treatment of mild to moderate actinic keratoses (ak) lesions on the face and scalp (hairless areas).

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - zoledronic acid monohydrate, quantity: 4.264 mg (equivalent: zoledronic acid, qty 4 mg) - injection, concentrated - excipient ingredients: sodium citrate dihydrate; mannitol; water for injections - zoledronic acid accord is indicated:,for the prevention of skeletal-related events (pathological fracture, spinal cord compression, radiation to bone or surgery to bone) in patients with advanced malignancies involving bone.,for treatment of tumour-induced hypercalcaemia.,as an adjunct to adjuvant treatment for women with early breast cancer who are in established menopause.

Australia - English - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - adrenaline (epinephrine) acid tartrate, quantity: 182 microgram/ml (equivalent: adrenaline (epinephrine), qty 100 microgram/ml) - injection, solution - excipient ingredients: sodium citrate dihydrate; sodium metabisulfite; dilute hydrochloric acid; water for injections; sodium chloride; citric acid monohydrate - adrenaline 1:10,000 is used as an adjunct in the management of cardiac arrest.

Australia - English - Department of Health (Therapeutic Goods Administration)

medsurge pharma pty ltd - tranexamic acid, quantity: 500 mg - injection, intravenous infusion - excipient ingredients: water for injections; sodium hydroxide; hydrochloric acid - intravenous administration,adults - for the reduction of peri? and post-operative blood loss and the need for blood transfusion in patients undergoing cardiac surgery or total knee arthroplasty or total hip arthroplasty.,paediatrics - for the reduction of peri? and post-operative blood loss and the need for blood transfusion in patients undergoing cardiac surgery.

United States - English - NLM (National Library of Medicine)

auromedics pharma llc - zoledronic acid (unii: 6xc1pad3kf) (zoledronic acid anhydrous - unii:70hz18ph24) - zoledronic acid anhydrous 4 mg in 5 ml - zoledronic acid injection is indicated for the treatment of hypercalcemia of malignancy defined as an albumin-corrected calcium (cca) of greater than or equal to 12 mg/dl [3.0 mmol/l] using the formula: cca in mg/dl = ca in mg/dl + 0.8 (4.0 g/dl - patient albumin [g/dl]). zoledronic acid injection is indicated for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. prostate cancer should have progressed after treatment with at least one hormonal therapy. limitations of use the safety and efficacy of zoledronic acid injection in the treatment of hypercalcemia associated with hyperparathyroidism or with other non−tumor-related conditions have not been established. hypersensitivity to zoledronic acid or any components of zoledronic acid injection hypersensitivity reactions including rare cases of urticaria and angioedema, and very rare cases of anaphylactic reaction/shock have been